Therapeutic Asset Ratings

164 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Abbv-319 Follicular Lymphoma	AbbVie	P1	C (37)
Abbv-400 Hepatocellular Carcinoma	AbbVie	P1	C (37)
Abbv-400 Pancreatic Ductal Adenocarcinoma	AbbVie	P1	C (37)
Abbv-400 Triple-Negative Breast Carcinoma	AbbVie	P1	C (37)
Abbv-453 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	AbbVie	P1	C (37)
Abbv-525 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	AbbVie	P1	C (37)
Abbv-969 Metastatic Prostate Carcinoma	AbbVie	P1	C (37)
Azirkitug Head And Neck Squamous Cell Carcinoma	AbbVie	P1	C (37)
Azirkitug Triple-Negative Breast Carcinoma	AbbVie	P1	C (37)
Budigalimab Head And Neck Squamous Cell Carcinoma	AbbVie	P1	C (37)
Budigalimab Neoplasm	AbbVie	P1	C (37)
Budigalimab Triple-Negative Breast Carcinoma	AbbVie	P1	C (37)
GILORALIMAB Cancer	AbbVie	P1	C (37)
Itraconazole Hepatocellular Carcinoma	AbbVie	P1	C (37)
Itraconazole Pancreatic Ductal Adenocarcinoma	AbbVie	P1	C (37)
MAB HUMANIZED (IGG1) ANTI P43489 (TNR4_HUMAN) (ABBV368) Cancer	AbbVie	P1	C (37)
Telisotuzumab Adizutecan Head And Neck Squamous Cell Carcinoma	AbbVie	P1	C (37)
Telisotuzumab Adizutecan Triple-Negative Breast Carcinoma	AbbVie	P1	C (37)
Abbv-295 Obesity Disorder	AbbVie	P1	C (36)
Abbv-400 Cancer	AbbVie	P1	C (36)
Abbv-400 Colorectal Cancer	AbbVie	P1	C (36)
Abbv-400 Non-Small Cell Lung Carcinoma	AbbVie	P1	C (36)
Abbv-438 Plasma Cell Myeloma	AbbVie	P1	C (36)
Abbv-706 Cancer	AbbVie	P1	C (36)
Abbv-787 Acute Myeloid Leukemia	AbbVie	P1	C (36)

Showing 126 to 150 of 164 assets